Repairing effects of glucosamine sulfate in combination with etoricoxib on articular cartilages of patients with knee osteoarthritis

Table 6 Inflammatory factors and MMPs (\( \overline{\mathrm{x}}\pm \mathrm{s} \))

Item	Experimental group (n = 66)	Control group (n = 40)	t	P
IL-1β (pg/mL)
Before treatment	74.37 ± 6.95	75.02 ± 7.14	0.462	0.645
After treatment	38.56 ± 3.74^ab	51.48 ± 4.89^a	15.322	0.000
IL-17 (μg/L)
Before treatment	391.64 ± 40.25	389.73 ± 39.52	0.238	0.812
After treatment	205.38 ± 19.76^ab	276.41 ± 26.11^a	15.858	0.000
IL-18 (pg/mL)
Before treatment	232.59 ± 24.16	241.25 ± 23.96	1.794	0.076
After treatment	148.73 ± 13.25^ab	184.67 ± 17.13^a	12.099	0.000
TNF-α (pg/mL)
Before treatment	87.94 ± 9.27	88.31 ± 9.56	0.197	0.844
After treatment	30.52 ± 2.86^ab	52.45 ± 5.02^a	28.679	0.000
MMP-3 (ng/ml)
Before treatment	217.93 ± 20.54	221.01 ± 21.18	0.739	0.461
After treatment	98.46 ± 9.75^ab	158.37 ± 14.82^a	21.359	0.000
MMP-9 (ng/ml)
Before treatment	66.83 ± 7.14	67.25 ± 7.21	0.292	0.770
After treatment	30.26 ± 2.97^ab	45.38 ± 4.62^a	20.524	0.000
MMP-13 (ng/ml)
Before treatment	275.18 ± 28.09	274.92 ± 27.83	0.046	0.963
After treatment	152.43 ± 14.72^ab	193.76 ± 18.69^a	10.987	0.000

Compared with before treatment, ^aP < 0.05; compared with control group, ^bP < 0.05. IL interleukin, MMP matrix metalloproteinase, TNF-α tumor necrosis factor-α

ISSN: 1749-799X